LEADING PUBLIC HEALTH EXPERTS TO OVERSEE DEVELOPMENT OFENHANCED CRUISE LINE HEALTH AND SAFETY STANDARDS“Healthy Sail Panel” comprises top experts in public health, infectious disease, biosecurity,hospitality and maritime operations
MIAMI, July 6, 2020 – Cruise industry leaders Royal Caribbean Group (NYSE: RCL) andNorwegian Cruise Line Holdings Ltd. (NYSE: NCLH) announced a collaboration to develop
enhanced cruise health and safety standards in response to the global COVID-19 pandemic.
The companies have asked Governor Mike Leavitt and Dr. Scott Gottlieb to serve as cochairs of a newly formed group of experts called the “Healthy Sail Panel.” The panel is tasked
with collaboratively developing recommendations for cruise lines to advance their public healthresponse to COVID-19, improve safety, and achieve readiness for the safe resumption ofoperations.
The expert panel has been working for nearly a month and will offer its initialrecommendations by the end of August. The cruise lines said its work will be “open source,”and could be freely adopted by any company or industry that would benefit from the group’s
scientific and medical insights.
“This unprecedented disease requires us to develop unprecedented standards in healthand safety,” said Richard D. Fain, chairman and CEO, Royal Caribbean Group. “Bringingaboard these respected experts to guide us forward demonstrates our commitment toprotecting our guests, our crews and the communities we visit.”“We compete for the vacationing consumer’s business every day, but we nevercompete on health and safety standards,” said Frank Del Rio, president and CEO, Norwegian
Cruise Line Holdings Ltd. “While the cruise industry has always had rigorous health standards,
the unique challenges posed by COVID-19 provide an opportunity to raise the bar evenhigher.”(more)

Healthy Sail Panel – Page 2“Health and safety are the highest priority for all CLIA cruise line members as
demonstrated by this initiative on the part of two of our largest members. We commend thisand parallel efforts of all of our members, large and small, who are working tirelessly todevelop appropriate protocols based on input from health authorities and medical experts inthe U.S. and abroad,” said Kelly Craighead, president and CEO of Cruise Lines InternationalAssociation (CLIA).
Fain and Del Rio said they initiated the panel to assure the plans they will submit to theU.S. Centers for Disease Control and Prevention (CDC) and other regulators apply the best
available public health, science and engineering insights. The work of the panel will be sharedwith the entire industry and regulators.
“In convening the Healthy Sail Panel, we sought the participation of a diverse group ofleading experts in areas of science and public health that are directly relevant to theconsiderations listed by the No Sail Order,” said Governor Leavitt. “We view our work as aprofoundly important public health effort. The health and safety of passengers, crew and thecommunities that cruise ships visit will be the principal focus of this project.”
Dr. Gottlieb said, “We know that the public health issues that must be addressed arecomplex, and in some areas, tackling them will require novel approaches. Our goal inassembling this team of leading experts was to develop best practices that can improve safety
and provide a roadmap for reducing the risks of COVID-19.”
The panel is co-chaired by Governor Leavitt, former Secretary of the U.S. Department
Health and Human Services (HHS), and Dr. Scott Gottlieb, former commissioner of the U.S.
Food and Drug Administration (FDA). The panel’s members are globally recognized experts
from various disciplines, including public health, infectious disease, biosecurity, hospitality andmaritime operations.

(more)

Healthy Sail Panel – Page 3
The members of the expert panel are:Governor Mike Leavitt

Dr. Scott Gottlieb

Mike Leavitt was a three-term
Governor of Utah and served
as Administrator of the EPA
and Secretary of HHS underPresident George W. Bush.
He is the founder of Leavitt
Partners, a firm that provides investment
support, data and analytics, member-based
alliances, and direct services to clients tosupport decision-making strategies in thevalue economy.

Dr. Scott Gottlieb was
the Commissioner of theFDA from 2017-2019
and served as theagency’s Deputy
Commissioner for
Medical and Scientific Affairs from 20052007. He is a physician trained in internal
medicine and is currently a resident fellow
at the American Enterprise Institute.

Helene Gayle, M.D., M.P.H.
Dr. Gayle is CEO of the Chicago Community Trust, one of the nation’s leading
community foundations. Prior to this role, for almost a decade, she waspresident and CEO of CARE, a leading international humanitarian organization.
An expert on global development, humanitarian and health issues, Dr. Gayle
spent 20 years with the CDC, working primarily on HIV/AIDS. She worked at
the Bill & Melinda Gates Foundation, directing programs on HIV/AIDS and otherglobal health issues. She also launched the McKinsey Social Initiative (now McKinsey.org), anonprofit that builds partnerships for social impact. Dr. Gayle serves on public company andnonprofit boards, including The Coca-Cola Company, Colgate-Palmolive Company, theBrookings Institution, the Center for Strategic and International Studies, New America, theONE Campaign, the Federal Reserve Bank of Chicago and the Economic Club of Chicago.
She is a member of the Council on Foreign Relations, the American Public Health Association,
the National Academy of Medicine, the National Medical Association and the American
Academy of Pediatrics.
Julie Gerberding, M.D., M.P.H.
Dr. Julie L. Gerberding is Executive Vice President and Chief Patient Officer forMerck, leading all aspects of strategic communications, global public policy,
population health and patient engagement. A former head of the CDC and aworld-renowned public health expert, Dr. Gerberding is deeply committed toachieving sustainable global health impact and tackling some of the mostchallenging health priorities of our time. This includes addressing critical issues
such as affordable access to important therapies, advocating for health policies that promoteand sustain innovation of new medicines and vaccines, and improving maternal mortality
through the Merck for Mothers program — a public-private partnership helping to meet theUnited Nations’ Sustainable Development Goal to reduce maternal mortality.

(more)

Healthy Sail Panel – Page 4Prior to joining Merck, Dr. Gerberding served as the Director of the CDC from 2002-2009 andwas the first female to hold that position. While at the agency, she led more than 40
emergency responses against crises such as anthrax, SARS, bird flu, foodborne outbreaks
and natural disasters. Previously, Dr. Gerberding was a tenured faculty member in Infectious
Diseases at the University of California at San Francisco (UCSF). She continues as an Adjunct
Associate Clinical Professor of Medicine at UCSF.
Steven Hinrichs, M.D.
Dr. Steven Hinrichs is Professor and Chair in the Department of Pathology andMicrobiology at the University of Nebraska Medical Center in Omaha, Directorof the University of Nebraska Center for Biosecurity and former Director of theNebraska Public Health Laboratory (NPHL). In his position as director of theuniversity’s center for biosecurity, he has been responsible for thedevelopment of a statewide program for the rapid identification of biologicalagents of mass destruction. He is principal investigator of multiple national awards from theAssociation of Public Health Laboratories (APHL) and the CDC and the U.S. Department ofDefense for the development of an outreach program to extend training and expertise in theearly recognition of biological warfare agents. Dr. Hinrichs received his MD from theUniversity of North Dakota and is board certified in Anatomical and Clinical Pathology. His
research laboratory focuses on molecular diagnostics and the role of viruses in cancer. Dr.
Hinrichs has published over 130 papers in basic science and medical journals.
Michael Osterholm, M.D., Ph.D.
Michael Osterholm is one of the nation’s foremost experts in public health,infectious disease and biosecurity. As the director of the Center for Infectious
Disease Research and Policy at the University of Minnesota, he is aninternational leader on the world’s preparedness for pandemics. He has led
numerous investigations into internationally important disease outbreaks,including foodborne diseases, hepatitis B in healthcare settings and HIV infectionin healthcare workers, and he is a frequent consultant to the World Health Organization, theNational Institutes of Health, the FDA, the U.S. Department of Defense and the CDC. From2001 to 2005, Dr. Osterholm served as a special advisor to the Secretary of HHS on issues
related to bioterrorism and public health preparedness. From June 2018 through May 2019, heserved as a Science Envoy for Health Security on behalf of the U.S. Department of State. He
has also been appointed to the National Science Advisory Board on Biosecurity and the World
Economic Forum’s Working Group on Pandemics, among other prominent advisory positions.

(more)

Healthy Sail Panel – Page 5
Stephen Ostroff, M.D.
Dr. Ostroff brings years of experience in public health, having served at high-level
positions at the FDA and the CDC. He was the Acting Commissioner of the FDA
from 2015-2016, and before that served as the FDA’s chief scientist. Ostroff
joined the FDA in 2013 as chief medical officer in the Center for Food Safety andApplied Nutrition and senior public health advisor to the FDA’s Office of Foods
and Veterinary Medicine. Prior to that he served as deputy director of theNational Center for Infectious Diseases at the CDC, where he was also acting
director of the CDC’s Select Agent Program. While at the CDC, he focused on emerging
infectious diseases, food safety and coordination of complex outbreak response. He retired
from the Commissioned Corps of the U.S. Public Health Service at the rank of Rear Admiral(Assistant Surgeon General). Ostroff was also the director of the Bureau of Epidemiology andacting physician general for the Commonwealth of Pennsylvania and has consulted
internationally on public health projects in South Asia and Latin America. Ostroff graduatedfrom the University of Pennsylvania School of Medicine in 1981 and completed residencies ininternal medicine at the University of Colorado Health Sciences Center and preventive
medicine at the CDC.
William Rutala, Ph.D., M.S., M.P.H.
Dr. Rutala has experience medically managing a variety of diseases andextensive experience studying epidemiology and virology, particularly managing
outbreaks and emerging pathogens. Dr. Rutala’s research interests are theetiology and prevention of healthcare-associated infections with a special focus
on disinfection and sterilization of reusable medical and surgical devices (e.g.,endoscopes, surgical instruments). Other areas of active research include
contribution of the hospital environment to disease transmission, hand hygiene, preventing
transmission of infectious agents, including multiply-drug resistant organisms, prevention ofhealthcare-associated Creutzfeldt-Jakob Disease, investigation of healthcare-associatedoutbreaks, and new and emerging pathogens in healthcare.
Kate Walsh, Ph.D.
Kate Walsh is the Dean at the School of Hotel Administration at Cornell
University and E.M. Statler Professor. A professor of management, she is aleader in education for the global hospitality industry; and a renowned expert inorganizational service design, leadership and career development, as well as
the impact of strategic human capital investments. In addition to authoring andcontributing to books, Dr. Walsh’s articles have appeared in numerous researchoutlets. She has over 20 years of academic experience, including in her current role as dean.
In addition, Dean Walsh holds extensive industry knowledge from serving as the former
director of training and development for Nikko Hotels International, corporate training manager
for the former Bristol Hotels, and senior auditor for Loews Corporation. She is also a former
New York State Certified Public Accountant.

(more)

Healthy Sail Panel – Page 6Since the beginning of her administration as dean, Dean Walsh has focused on positioning theschool for the future of education. This includes undertaking a comprehensive renewal of thegraduate and undergraduate curricula, developing the school's online global presence,identifying international partners for master-level program development, and providing thought
leadership for the hospitality industry, most notably through the creation of industry research
partnerships for faculty, fostering new initiatives through the school's six centers and institutes,
and providing faculty-developed resources to guide the industry. Dr. Walsh received her Ph.D.
from the Carroll School of Management at Boston College and her M.P.S. degree fromCornell’s School of Hotel Administration.
Captain Patrik Dahlgren
Captain Patrik Dahlgren is the Senior Vice President of Global Marine
Operations and Fleet Optimization for all Royal Caribbean Group globalbrands. Dahlgren’s seagoing experiences started as a bridge officer aboard
tugboats, yachts and an array of cargo vessels and ferries. He rose through theranks with over 15 years onboard Royal Caribbean International cruise ships,with his last seagoing command as Master of Oasis of the Seas and Quantumof the Seas. He was a lead contributor to the Quantum of the Seas development and received
the esteemed RINA (Royal Institute of Naval Architects) award for its innovation andcontributions to maritime safety.
Robin Lindsay
Robin Lindsay is the Executive Vice President of Vessel Operations forNorwegian Cruise Line Holdings Ltd. Lindsay was appointed to this position inJanuary 2015. In this role, Lindsay is responsible for Marine & TechnicalOperations, Hotel Operations, Entertainment, Product Development, Port &Destination Services, Fleet Personnel, Out Islands and New Build & Ship
Refurbishment for all three of the company's brands – Norwegian Cruise Line,
Oceania Cruises and Regent Seven Seas Cruises.
Prior to joining Norwegian Cruise Line Holdings Ltd., Lindsay served in a similar capacity as
Executive Vice President of Vessel Operations at Prestige Cruise Holdings, the parent
company of Oceania Cruises and Regent Seven Seas Cruises. Lindsay's history with thecompany goes back to the inception of Oceania Cruises in 2003, where he joined as SeniorVice President, Hotel Operations and Vessel Operations. Lindsay earned his B.S. degree fromLouisiana Tech University.

(more)

Healthy Sail Panel – Page 7
In addition, several experts will also serve as senior advisors to the panel, including Dr.
Caitlin Rivers, who is a faculty member and epidemiologist at the Johns Hopkins BloombergSchool of Public Health and an expert in emerging infectious disease epidemiology andoutbreak science, and Dr. Phyllis Kozarsky, who is a professor emerita of medicine in theDivision of Infectious Diseases at Emory University School of Medicine and an expert in pretravel health advice and education, global health, and the epidemiology of travel-related
infections and infectious diseases. Dr. Kozarsky serves as an expert consultant to the Divisionof Global Migration and Quarantine in travelers’ health with the CDC.
About Royal Caribbean GroupRoyal Caribbean Group (NYSE: RCL) is a global cruise vacation company that controls and operates four global
brands: Royal Caribbean International, Celebrity Cruises, Azamara and Silversea Cruises. The Company is also a
50% joint venture owner of the German brand TUI Cruises and a 49% shareholder of the Spanish brandPullmantur. Together these brands operate a combined total of 62 ships with an additional 16 on order as ofMarch 31, 2020. They operate diverse itineraries around the world that call on all seven continents. Additional
information can be found on www.royalcaribbean.com, www.celebritycruises.com, www.azamara.com,
www.silversea.com, www.tuicruises.com, www.pullmantur.es, www.rclcorporate.com or www.rclinvestor.com.
About Norwegian Cruise Line Holdings Ltd.
Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) is a leading global cruise company which operates theNorwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises brands. With a combined fleet of 28
ships with approximately 59,150 berths, these brands offer itineraries to more than 490 destinations worldwide. The
Company will introduce nine additional ships through 2027.
Cautionary Statement Concerning Forward-Looking StatementsSome of the statements contained in this release are “forward-looking statements” within the meaning of the U.S. federal
securities laws intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of1995. All statements other than statements of historical facts contained in this release, including, without limitation, thoseregarding business strategies, plans, and objectives for future operations (including those regarding efforts made by the panel
and future health and safety protocols) are forward-looking statements. Many, but not all, of these statements can be found bylooking for words like “expect,” “plan,” “will,” “may,” and similar words. Forward-looking statements do not guarantee future
performance and may involve risks, uncertainties and other factors which could cause actual results, performance orachievements to differ materially from the future results, performance or achievements expressed or implied in those forwardlooking statements. Examples of these risks, uncertainties and other factors include, but are not limited to the impact of: thespread of epidemics, pandemics and viral outbreaks and specifically, the COVID-19 outbreak, including its effect on the ability
or desire of people to travel (including on cruises); the ability to develop strategies to enhance health and safety protocols toadapt to the current pandemic environment’s unique challenges once operations resume and to otherwise safely resume
operations when conditions allow; coordination and cooperation with the CDC, the federal government and global public healthauthorities to take precautions to protect the health, safety and security of guests, crew and the communities visited and theimplementation of any such precautions; and other factors set forth under “Risk Factors” in each respective company’s mostrecently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q and subsequent filings with the Securities andExchange Commission. It is not possible to predict or identify all such risks. There may be additional risks that are considered
immaterial or which are unknown. The above examples are not exhaustive and new risks emerge from time to time. Suchforward-looking statements are based on current beliefs, assumptions, expectations, estimates and projections regarding
present and future business strategies and the environment in which we expect to operate in the future. These forward-looking
statements speak only as of the date made. We expressly disclaim any obligation or undertaking to release publicly any updates
or revisions to any forward-looking statement to reflect any change in our expectations with regard thereto or any change ofevents, conditions or circumstances on which any such statement was based.

(more)

Healthy Sail Panel – Page 8
Media Contacts
Royal Caribbean GroupRob Zeiger
corporatecommunications@rccl.com
Norwegian Cruise Line Holdings Ltd.
Andrea DeMarcoNCLHMedia@nclcorp.com
Healthy Sail Panel
Sara Singleton
Sara.Singleton@LeavittPartners.com